← Back
American Healthcare REIT
AHR · listed on the New York Stock Exchange · worth $11.05 billion
$53.55
+0.86% on Oct 28
No insider bought American Healthcare REIT stock in the last year. They sold it 7 times, $5.22 million in all.
Red dot = an insider soldA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
216.6M shares
99% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, three insiders sold American Healthcare REIT stock and none bought. One of the 7 sales is marked on the filing as planned in advance; most by company executives. The biggest seller was Jeffrey T. Hanson.
Planned sales
Form 144 notices filed for American Healthcare REIT in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Executive Mark E. Foster filed to sell 1,500 shares on 25 Sep; no sale reported yetNotice on SEC.gov
Executive Mark E. Foster filed to sell 2,000 shares on 1 Sep; sold 2,000 by 1 Sep10b5-1 plan adopted 19 Dec 2025 · Notice on SEC.gov
Big investors
People and funds that reported owning 5% or more of American Healthcare REIT, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company.State Street4.3%Aug 7
All reports
Every insider trade and SEC report we hold for American Healthcare REIT.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Sep 1SoldMark E. FosterSep 1 · EVP, GC & Secretary · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.2,000 @ $55.39$110.8K
Dec 29, 2025SoldJeffrey T. HansonDec 29, 2025 · Traded Dec 23, 2025 · Directorvia a trust or family19,208 @ $48.40$929.7K
Dec 29, 2025SoldJeffrey T. HansonDec 29, 2025 · Traded Dec 22, 2025 · Directorvia a trust or family35,570 @ $48.38$1.72M
4 more with Pro →Analysts, earnings and news
Analysts' price target
$64.00 average
15 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
2 of 4 quarters above
Q2 '26$0.15 a share+$0.02
Q1 '26$0.14 a share−$0.01
Q4 '25$0.14 a share−$0.01
Q3 '25$0.27 a share+$0.11